Acuta Capital Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Acuta Capital Partners’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-71,500	Closed	-$1.01M	–	48
2022 Q2	$1.01M	Buy	+71,500	New	+$1.33M	0.56%	34
2018 Q1	–	Sell	-90,000	Closed	-$2.71M	–	61
2017 Q4	$2.71M	Sell	90,000 -80,000	-47%	-$2.56M	0.51%	27
2017 Q3	$6.4M	Sell	170,000 -80,000	-32%	-$2.6M	1.15%	20
2017 Q2	$6.97M	Sell	250,000 -322,756	-56%	-$9.62M	1.95%	15
2017 Q1	$19.7M	Buy	572,756 +272,756	+91%	+$9.63M	4.67%	7
2016 Q4	$8.65M	Buy	300,000 +80,000	+36%	+$2.12M	3.22%	12
2016 Q3	$7M	Buy	220,000 +134,001	+156%	+$4.54M	2.63%	11
2016 Q2	$2.79M	Buy	+85,999	New	+$2.88M	1.34%	22

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Acuta Capital Partners's ACAD Position: Q3 2022 in Review

Acuta Capital Partners sold out of Acadia Pharmaceuticals (ACAD) in Q3 2022, closing a stake of 71,500 shares — an estimated $1.01M sold.

Acuta Capital Partners first reported a position in ACAD in Q2 2016 and held it in 8 quarters. The position peaked at $19.7M in Q1 2017. 223 funds tracked by Wall St. Rank hold ACAD as of Q3 2022.

Acuta Capital Partners reported no remaining Acadia Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Acuta Capital Partners sold 71,500 Acadia Pharmaceuticals shares in Q3 2022, an estimated $1.01M.
Acuta Capital Partners first reported a position in Acadia Pharmaceuticals in Q2 2016 and held it in 8 quarters.
Acuta Capital Partners's Acadia Pharmaceuticals position peaked at $19.7M in Q1 2017.
223 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2022.

Based on Acuta Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.